2-Chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis

Mayo Clinic Proceedings

Volumn 78, Issue 3, 2003, Pages 301-306

  Pardanani, Animesh ^a   Phyliky, Robert L ^a   Li, Chin Yang ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CORTICOSTEROID; ETOPOSIDE; PREDNISONE; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; EVALUATION; FEMALE; FOLLOW UP; HERPES ZOSTER; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MEDICAL RECORD; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; SALVAGE THERAPY; THROMBOCYTOPENIA; TUMOR BIOPSY;

EID: 0037373124     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.3.301     Document Type: Article

References (25)

1. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer. 1999;85:2278-2290.
2. Malpas JS. Langerhans cell histiocytosis in adults. Hematol Oncol Clin North Am. 1998;12:259-268.
3. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002;346:484-490.
4. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:327-338.
5. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:339-357.
6. Saven A, Figueroa ML, Piro LD, Rosenblatt JD. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med. 1993;329:734-735.
7. Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med. 1994;121:430-432.
8. Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood. 1999;93:4125-4130.
9. Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. 1999;33:476-481.
10. Daoud MS, Dahl PR, Dicken CH, Phyliky RL. Indeterminate cell histiocytosis treated successfully with 2-chlorodeoxyadenosine. Cutis. 1997;59:27-31.
11. Schmitz L, Favara BE. Nosology and pathology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:221-246.
12. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75:377-383.
13. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol Cell Ther. 1996;38(suppl 2):S93-S101.
14. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blaldey RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992;10:364-370.
15. Saven A, Piro L. Newer purine analogues for the treatment of hairycell leukemia. N Engl J Med. 1994;330:691-697.
16. Carrera CJ, Terai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo: a novel approach to immunosuppressive therapy. J Clin Invest. 1990;86:1480-1488.
17. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 1995;13:570-574.
18. Grau J, Ribera JM, Tormo M, et al. Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis: study of 9 patients [in Spanish]. Med Clin (Barc). 2001;116:339-342.
19. Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye. 2000;14:606-612.
20. Conias S, Strutton G, Stephenson G. Adult cutaneous Langerhans cell histiocytosis. Australas J Dermatol. 1998;39:106-108.
21. Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288-292.
22. Dimopoulos MA, Theodorakis M, Kostis E, Papadimitris C, Moulopoulos LA, Anastasiou-Nana M. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leuk Lymphoma. 1997;25:187-189.
23. Dallafior S, Pugin P, Cerny T, Betticher D, Saurat JH, Hauser C. Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide [in German]. Hautarzt. 1995;46:553-560.
24. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine (CdA) in cerebrospinal fluid (CSF) [abstract]. Blood. 1992;80(suppl):471a.
25. Grois NG, Favara BE, Mostbeck GH, Prayer D. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998;12:287-305.